Abstract
This retrospective study included 73 eyes of 73 glaucoma patients and 75 eyes of 75 individuals with glaucoma suspect (control group). Newly diagnosed glaucoma patients with no previous glaucoma treatment were administered latanoprost 0.005% (n = 27) or bimatoprost 0.03% (n = 24) or travoprost 0.004% (n = 22) monotherapy once a day. CCTs were measured by ultrasound pachymetry before treatment and followed up annually for 5 years.
Highlights
Prostaglandin (PG) analogues are being widely used to reduce Intraocular Pressure (IOP) in glaucoma patients
We observed a decrease in Central Corneal Thickness (CCT) 4.7 μm in latanoprost group, 6.7 μm in bimatoprost group and 6.4 μm/per year in travoprost group
Corneal thinning after topical PG analogues treatment could result in underestimation of IOP levels as measured by Goldmann Applanation Tonometry (GAT)
Summary
Prostaglandin (PG) analogues are being widely used to reduce Intraocular Pressure (IOP) in glaucoma patients These drugs reduce IOP by stimulation of aqueous humor drainage primarily through the uveoscleral outflow pathway but significant effects on trabecular outflow facility have been reported [1]. The suggested mechanism of IOP reduction involves aqueous humor outflow enhancement through the uveoscleral pathway accompanied by collagen degradation in the ciliary body. This collagen degradation is believed to be mediated by Matrix Metalloproteinases (MMPs) induced by prostaglandin F2-alpha [2,3]. Elevated IOP is a risk factor for glaucoma and it’s believed that to decrease the IOP values is the first choice of treatment in glaucoma [5]. Besides its importance in IOP measurements it’s been suggested that CCT is an independent risk factor of progression in open angle glaucoma [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
